17 November 2023 Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101 read more
13 November 2023 Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer read more
9 November 2023 Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis read more
31 October 2023 Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting read more
30 October 2023 Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors read more
